Lu C, Yin Y, Meng F, Dun Y, Pei K, Wang C. Discovery of (E)-1-amino-4-phenylbut-3-en-2-ol derivatives as novel neuraminidase inhibitors. Bioorg Med Chem Lett. 2018 May 4. pii: S0960-894X(
Neuraminidase has been considered as an important target for designing agents against influenza viruses. In a discovery of anti-influenza agents with epigoitrin as the initial lead compound, a series of 1-amino-2-alkanols were synthesized and biologically evaluated. The in vitro evaluation indicated that (E)-1-amino-4-phenylbut-3-en-2-ol (C1) had better inhibitory activities than 2-amino-1-arylethan-1-ol derivatives. To our surprise, sulfonation of C1 with 4-methoxybenzenesulfonyl chloride afforded more active inhibitor II with up to 6.4?μM IC50 value against neuraminidase. Furthermore, docking of inhibitor II into the active site of NA found that the H atoms in both NH2 and OH groups of inhibitor II were the key factors for potency. Molecular docking research did not explained very well the observed structure-activity relationship (SAR) from amino acid residue level, but also aided the discovery of (E)-1-amino-4-phenylbut-3-en-2-ol derivatives as novel and potent NA inhibitors.
See Also:
Latest articles in those days:
- First human case of avian influenza A (H10N3) in Southwest China [preprint] 2 days ago
- Molecular characterization of the whole genome of H9N2 avian influenza virus isolated from Egyptian poultry farms 2 days ago
- Genetic drift and purifying selection shape within-host influenza A virus populations during natural swine infections 2 days ago
- High-pathogenicity avian influenza in wildlife: a changing disease dynamic that is expanding in wild birds and having an increasing impact on a growing number of mammals 4 days ago
- Avian Influenza Virus and Avian Paramyxoviruses in Wild Waterfowl of the Western Coast of the Caspian Sea (2017–2020) 5 days ago
[Go Top] [Close Window]